Abstract: The present disclosure relates to a portable printer including a main body in a portable form which is capable of accommodating a cartridge having a nozzle for delivering a printing material to a target having a soft or hard surface, a seating part which is provided to be exposed to an outside from a lower portion of the main body to face the surface of the target and at least partially surrounds the nozzle, a roller provided respectively at the front and rear of the nozzle at the lower portion of the main body with respect to a direction in which the main body moves along the surface of the target to deliver the printing material to the target, and a printing adjustment unit configured to adjust a height difference between the nozzle and the roller to adjust a height difference between the nozzle and the surface of the target.

Abstract: The present invention provides a backlight module comprising a light emitting unit including a light source and a light guide plate transmitting light from the light source; a light guide unit accumulatively placed on the top of the light emitting unit and transmitting the light to the upper part of the light guide unit; a mold frame containing the light emitting unit and the light guide unit and having a space between the side of the light guide unit and the mold frame; and a shielding portion formed at the side of the light guide unit to prevent light leakage transmitting from the side of the light guide unit to the outside of the light guide unit.

Abstract: The present invention provides a backlight module comprising a light emitting unit including a light source and a light guide plate transmitting light from the light source; a light guide unit accumulatively placed on the top of the light emitting unit and transmitting the light to the upper part of the light guide unit; a mold frame containing the light emitting unit and the light guide unit and having a space between the side of the light guide unit and the mold frame; and a shielding portion formed at the side of the light guide unit to prevent light leakage transmitting from the side of the light guide unit to the outside of the light guide unit.

Abstract: An organic waste treatment apparatus according to the present disclosure includes an acid fermenter 140, a methane fermenter 150, a thickener tank 300, and a separation membrane device 400, and includes: a first circulation line 141 in which a first circulation pump 141a is installed in a linked manner so that a part of organic waste being acid-fermented in the acid fermenter 140 is supplied to the methane fermenter 150; and a second circulation line 151 in which a second circulation pump 151a is installed in a linked manner so that a part of a anaerobic digestive fluid being methane-fermented in the methane fermenter 150 is supplied to the acid fermenter 140, in which the thickener tank 300 is installed between the methane fermenter 150 and the separation membrane device 400, supplied with concentrated circulating water from the separation membrane device 400, and supplies at least a part of the supplied concentrated circulating water to the methane fermenter 150 in an indirect injection manner, such that a

Abstract: The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by D. pteronissinus extract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of Styrax japonica, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-?1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of asthma comprising Wogonin as an active ingredient. The Wogonin of the present invention is excellent not only in relieving airway hypersensitivity that causes asthma in vivo, in inhibiting reactive oxygen species generation in the airway, and in inhibiting the infiltration of inflammatory cells in the bronchus, but also in inhibiting the generation of IgE in serum and bronchoalveolar lavage fluid, and in inhibiting the expressions of Th2 cytokines in the lung. Therefore, the Wogonin of the present invention can be effectively used as a composition for the prevention, treatment, or improvement of asthma.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of Styrax japonica, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-?1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

Abstract: The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by D. pteronissinus extract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.